Skip to main content

Table 1 Clinicopathologic and molecular characteristics of patients with DLBCL with a low or high degree of SHM in immunoglobulin variable region genes

From: Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

 IGHV SHMlowIGHV SHMhighPIGK/LV SHMlowIGK/LV SHMhighP
n (%)n (%)n (%)n (%)
Age
  < 60 years32 (44%)25 (36%).3166 (40%)14 (37%).72
  ≥ 60 years40 (56%)45 (64%) 97 (60%)24 (63%) 
Sex
 Male35 (49%)41 (59%).2494 (58%)26 (68%).27
 Female37 (51%)29 (41%) 69 (42%)12 (32%) 
Stage
 I - II29 (43%)34 (52%).3972 (46%)14 (39%).58
 III - IV39 (57%)32 (48%) 86 (54%)22 (61%) 
B symptoms
 No38 (56%)43 (63%).48103 (66%)28 (78%).23
 Yes30 (44%)25 (37%) 53 (34%)8 (22%) 
Serum LDH level
 Normal21 (33%)29 (45%).2067 (46%)18 (55%).44
 Elevated43 (67%)35 (55%) 78 (54%)15 (45%) 
No. of extranodal sites
 0 or 151 (76%)53 (82%).53126 (81%)26 (70%).18
  ≥ 216 (24%)12 (18%) 30 (19%)11 (30%) 
ECOG performance status
 0 or 147 (80%)44 (76%).66113 (79%)26 (81%)1.0
  ≥ 212 (20%)14 (24%) 30 (21%)6 (19%) 
Largest tumor size
  < 5 cm37 (66%)27 (53%).1773 (57%)13 (43%).22
  ≥ 5 cm19 (34%)24 (47%) 55 (43%)17 (57%) 
IPI score
 0–240 (60%)42 (64%).7297 (62%)21 (57%).58
 3–527 (40%)24 (36%) 60 (38%)16 (43%) 
Therapy response
 CR51 (71%)54 (77%).45*126 (77%)27 (73%).67*
 PR108 213 
 SD23 41 
 PD95 126 
ABC subtype/ABC subtype
 GCB27 (39%)39 (53%).09478 (47%)21 (57%).36
 ABC43 (61%)34 (47%) 88 (53%)16 (43%) 
BAGS classification
 CC/CB24 (52%)40 (75%).0277 (64%)21 (81%).11
 Others22 (48%)13 (25%) 43 (36%)5 (19%) 
BCL2 translocation
 No55 (87%)46 (72%).047125 (81%)22 (65%).042
 Yes8 (13%)18 (28%) 29 (19%)12 (35%) 
MYC expression
 < 70%39 (57%)50 (72%).047117 (72%)26 (68%).69
 ≥ 70%29 (43%)19 (28%) 46 (28%)12 (32%) 
PI3K expression
 < 70%43 (67%)50 (75%).44112 (72%)14 (42%).0018
 ≥ 70%21 (33%)17 (25%) 43 (28%)19 (58%) 
p63 expression
 < 10%47 (68%)38 (54%).08693 (59%)14 (39%).04
 ≥ 10%22 (32%)33 (46%) 65 (41%)22 (61%) 
CD30 expression
  < 20%58 (83%)60 (83%)1.0135 (82%)37 (97%).012
  ≥ 20%12 (17%)12 (17%) 30 (18%)1 (3%) 
p65 expression
  < 10%22 (35%)29 (43%).4761 (41%)7 (21%).031
  ≥ 10%40 (65%)39 (57%) 89 (59%)27 (79%) 
CXCR4 expression
  < 20%43 (73%)47 (70%).84109 (72%)19 (53%).029
  ≥ 20%16 (27%)20 (30%) 42 (28%)17 (47%) 
  1. Abbreviations: IGHV Immunoglobulin heavy chain variable region gene, IGK/LV Immunoglobulin kappa or lambda light chain variable region gene, SHMlow Low degree of somatic hypermutation, SHMhigh High degree of somatic hypermutation, LDH Lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, GCB germinal center B-cell–like, ABC Activated B-cell–like, BAGS B-cell–associated gene signature, CB Centroblast subtype, CC Centrocyte subtype
  2. Note: Not all patients had data available. Significant P values (Fisher’s exact test) are in bold. *For therapy response, P values were for comparisons between CR and non-CR cases